The Search for Genomic Biomarkers of Response to Immunotherapy in Ovarian Cancer

被引：6

作者：

Al-Rawi, Duaa H. ^{[1
,2
]}

Rusk, Nicole ^{[2
]}

Friedman, Claire F. ^{[1
,3
,4
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Computat Oncol, New York, NY USA

[3] Weill Cornell Med Coll, Dept Med, New York, NY USA

[4] 300 East 66th Str,Room 1349, New York, NY 10065 USA

来源：

CLINICAL CANCER RESEARCH | 2023年 / 29卷 / 09期

基金：

美国国家卫生研究院;

关键词：

BEVACIZUMAB;

D O I：

10.1158/1078-0432.CCR-23-0048

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint blockade has been ineffective in ovarian cancer, and there is an ongoing effort to identify biomarkers of therapeutic benefit. Despite promising preclinical data, a substudy of the IMagyn050 trial found that patients with homologous recombination deficient tumors did not have improved progression-free survival with the addition of the PD-L1 inhibitor atezolizumab. See related article by Landen et al., p. 1698

引用

页码：1645 / 1647

页数：3

共 50 条

[1] Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary
Posner, Atara
Sivakumaran, Tharani
Pattison, Andrew
Etemadmoghadam, Dariush
Thio, Niko
Wood, Colin
Fisher, Krista
Webb, Samantha
DeFazio, Anna
Wilcken, Nicholas
Gao, Bo
Karapetis, Christos S.
Singh, Madhu
Collins, Ian M.
Richardson, Gary
Steer, Christopher
Warren, Mark
Karanth, Narayan
Fellowes, Andrew
Fox, Stephen B.
Hicks, Rodney J.
Schofield, Penelope
Bowtell, David
Prall, Owen W. J.
Tothill, Richard William
Mileshkin, Linda
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (01)
[2] Frequency of genomic biomarkers of response to immunotherapy in sarcoma.
Trabucco, Sally E.
Ali, Siraj Mahamed
Sokol, Ethan
Schrock, Alexa Betzig
Albacker, Lee A.
Chung, Jon
Xavier, Marin Feldman
Disel, Umut
Miller, Vincent A.
Ross, Jeffrey S.
Frampton, Garrett Michael
Wilky, Breelyn A.
Ravi, Vinod
Gounder, Mrinal M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[3] Biomarkers that may predict response to immunotherapy in ovarian malignancies
Chin, Curtis D.
Fares, Charlene M.
Konecny, Gottfried E.
Rao, Jianyu
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2020, 32 (01) : 84 - 90
[4] Molecular Biomarkers of Response to Cancer Immunotherapy
Ritterhouse, Lauren L.
Gogakos, Tasos
CLINICS IN LABORATORY MEDICINE, 2022, 42 (03) : 469 - 484
[5] Comprehensive genomic profiling to identify biomarkers predictive of response to immunotherapy
Noel, Pawan
Hall, David W.
Udhane, Sameer S.
Wang, Min
Alyaqoub, Fadel S.
Szelinger, Szabolcs
Ozols, Audrey A.
LoBello, Janine R.
Baehner, Frederick L.
Basu, Gargi D.
CANCER RESEARCH, 2022, 82 (12)
[6] Non-genomic biomarkers of risk in ovarian cancer
Pinheiro, Simone P.
Cramer, Daniel W.
DISEASE MARKERS, 2007, 23 (5-6) : 355 - 366
[7] Ovarian cancer biomarkers: A focus on genomic and proteomic findings
Tinelli, Andrea
Vergara, Daniele
Martignago, Roberta
Leo, Giuseppe
Malvasi, Antonio
Tinelli, Raffaele
Marsigliante, Santo
Maffia, Michele
Lorusso, Vito
CURRENT GENOMICS, 2007, 8 (05) : 335 - 342
[8] Circulating biomarkers of response to immunotherapy in cancer treatment
Del Re, Marzia
Gianfilippo, Giulia
Crucitta, Stefania
Addeo, Alfredo
van Schaik, Ron H. N.
Danesi, Romano
PHARMACOGENOMICS, 2019, 20 (18) : 1247 - 1249
[9] Biomarkers for immunotherapy response in head and neck cancer
Gavrielatou, Niki
Doumas, Stergios
Economopoulou, Panagiota
Foukas, Periklis G.
Psyrri, Amanda
CANCER TREATMENT REVIEWS, 2020, 84
[10] Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer
Sharma Saha, Sweta
Gentles, Lucy
Bradbury, Alice
Brecht, Dominik
Robinson, Rebecca
O'Donnell, Rachel
Curtin, Nicola J.
Drew, Yvette
CANCERS, 2021, 13 (06) : 1 - 17

← 1 2 3 4 5 →